Table 1 Baseline characteristics of patients readmitted within 1 year
Characteristic | Readmitted | Not Readmitted | Overall | p value |
|---|---|---|---|---|
N = 462 | N = 475 | N = 937 | ||
Demographics | ||||
Age, median (IQR) | 84 (79–87) | 83 (78–87) | 83 (78–87) | 0.14 |
Female | 204 (44.2%) | 211 (44.4%) | 415 (44.3%) | 0.94 |
Baseline living status | ||||
Independent | 366 (79.2%) | 400 (84.2%) | 766 (81.8%) | 0.10 |
Dependent | 87 (18.8%) | 65 (13.7%) | 152 (16.2%) | |
Cardiac Risk Factors | ||||
Diabetes | 230 (49.8%) | 224 (47.2%) | 454 (48.5%) | 0.42 |
Dyslipidemia | 330 (71.4%) | 326 (68.6%) | 656 (70.0%) | 0.35 |
Hypertension | 448 (97.0%) | 448 (94.3%) | 896 (95.6%) | 0.05 |
Clinical Characteristics | ||||
NYHA Class | ||||
I or II | 64 (13.9%) | 82 (17.3%) | 146 (15.6%) | 0.01 |
III | 290 (62.8%) | 308 (64.8%) | 598 (63.8%) | |
IV | 83 (18.0%) | 52 (10.9%) | 135 (14.4%) | |
Frailty | 70 (15.2%) | 54 (11.4%) | 124 (13.2%) | 0.09 |
Weight (kg), median (IQR) | 72 (62–82) | 73 (62–84) | 72 (62–83) | 0.30 |
Cardiac comorbidities and interventions | ||||
Atrial fibrillation | 175 (37.9%) | 124 (26.1%) | 299 (31.9%) | < 0.001 |
Prior heart failure | 232 (50.2%) | 179 (37.7%) | 411 (43.9%) | < 0.001 |
Prior myocardial infarction | 115 (24.9%) | 94 (19.8%) | 209 (22.3%) | 0.06 |
Prior PCI | 166 (35.9%) | 135 (28.4%) | 301 (32.1%) | 0.01 |
Prior CABG | 133 (28.8%) | 172 (36.2%) | 305 (32.6%) | 0.02 |
Prior AVR | 35 (7.6%) | 40 (8.4%) | 75 (8.0%) | 0.63 |
Medical comorbidities | ||||
Cerebrovascular disease | 38 (8.2%) | 38 (8.0%) | 76 (8.1%) | 0.90 |
Peripheral vascular disease | 92 (19.9%) | 74 (15.6%) | 166 (17.7%) | 0.08 |
Dementia | 12 (2.6%) | 8 (1.7%) | 20 (2.1%) | 0.33 |
Dialysis | 26 (5.6%) | 6 (1.3%) | 32 (3.4%) | < 0.001 |
Lung disease | 105 (22.7%) | 60 (12.6%) | 165 (17.6%) | < 0.001 |
Cancer | 67 (14.5%) | 50 (10.5%) | 117 (12.5%) | 0.07 |
Liver disease | 10 (2.2%) | 6 (1.3%) | 16 (1.7%) | 0.29 |
Peptic ulcer disease | 34 (7.4%) | 12 (2.5%) | 46 (4.9%) | < 0.001 |
Prior bleeding history | 138 (29.9%) | 90 (18.9%) | 228 (24.3%) | < 0.001 |
Laboratory markers | ||||
eGFR, median (IQR) | 54 (39–70) | 62 (46–78) | 58 (42–74) | < 0.001 |
Hemoglobin (g/L), median (IQR) | 117 (105–129) | 124 (113–134) | 120 (109–132) | < 0.001 |
Echocardiographic findings | ||||
Aortic valve area (cm2), mean ± SD | 0.68 ± 0.22 | 0.70 ± 0.24 | 0.69 ± 0.23 | 0.16 |
Mean AoV (mmHg), mean ± SD | 46 ± 15 | 46 ± 16 | 46 ± 16 | 0.80 |
Left ventricular dysfunction | 120 (26.0%) | 135 (28.4%) | 255 (27.2%) | 0.42 |
Composite measures | ||||
EuroScore II (%), mean ± SD | 0.07 ± 0.07 | 0.07 ± 0.05 | 0.07 ± 0.06 | 0.06 |
Charlson Score, mean ± SD | 2.72 ± 2.19 | 1.97 ± 1.91 | 2.34 ± 2.09 | < 0.001 |
Hospitalization 30 days before TAVR | 147 (31.8%) | 116 (24.4%) | 263 (28.1%) | 0.01 |
Transitional care factors (≤30 days) | ||||
In-patient rehabilitation | 79 (17.1%) | 41 (8.6%) | 120 (12.8%) | < 0.001 |
Home care utilization | 204 (44.2%) | 167 (35.2%) | 371 (39.6%) | 0.005 |
Family physician follow-up | 382 (82.7%) | 405 (85.3%) | 787 (84.0%) | 0.28 |
Cardiologist follow-up | 303 (65.6%) | 258 (54.3%) | 561 (59.9%) | < 0.001 |